Intravitreal Ranibizumabe — Competitive Intelligence Brief

Intravitreal Ranibizumabe (Intravitreal Ranibizumabe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF-A inhibitor; monoclonal antibody fragment. Area: Ophthalmology.

marketed VEGF-A inhibitor; monoclonal antibody fragment VEGF-A (Vascular Endothelial Growth Factor A) Ophthalmology Small molecule

Target snapshot

Intravitreal Ranibizumabe (Intravitreal Ranibizumabe) — University of Sao Paulo. Ranibizumab is a monoclonal antibody fragment that blocks vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravitreal Ranibizumabe TARGET	Intravitreal Ranibizumabe	University of Sao Paulo	marketed	VEGF-A inhibitor; monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis every 12 weeks	Lucentis every 12 weeks	Retinal Consultants of Arizona	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Lucentis (ranibizumab)	Lucentis (ranibizumab)	Samsung Bioepis Co., Ltd.	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab (Lucentis)	Ranibizumab (Lucentis)	Greater Houston Retina Research	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Intravitreal ranibizumab	Intravitreal ranibizumab	LEANDRO CABRAL ZACHARIAS	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF-A inhibitor; monoclonal antibody fragment class)

1. University of Sao Paulo · 1 drug in this class